To Evaluate the Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine as Pulpotomy Medicament in Patients With Pulpitis.
Overview
- Phase
- Phase 4
- Intervention
- Mineral trioxide aggregate
- Conditions
- Pulpitis - Irreversible
- Sponsor
- Maharishi Markendeswar University (Deemed to be University)
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- EPT
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The aim of this study was to clinically and radiographically evaluate the effectiveness of MTA, Biodentine, Platelet Rich Fibrin along with Mineral Trioxide Aggregate and Platelet Rich Fibrin along with Biodentine as pulpotomy medicament in patients with pulpitis.
Detailed Description
Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated into 4 groups (15 each) Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP: Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent Patients were assessed at 1 day,3 months, 6 months and 9 months postoperatively for pain, pulp sensitivity test, swelling or presence of any sinus tract. All the proposed teeth were assessed radiographically at1 day, 3 months, 6 months and 9 months postoperatively.
Investigators
DR SURINDER SACHDEVA
PROFESSOR
Maharishi Markendeswar University (Deemed to be University)
Eligibility Criteria
Inclusion Criteria
- •Patients with carious exposed tooth exhibiting clinical and radiographical evidence for pulpitis.
- •Deep caries extending ≥2/3 of dentin.
- •Tooth with positive response with cold testing.
- •Tooth with no mobility.
- •No signs of pulpal necrosis including sinus tract or swelling.
- •Patient approval for the treatment and follow up
Exclusion Criteria
- •Any systemic disease that could influence the outcome.
- •Non-restorable tooth.
- •Teeth with periapical widening.
- •Tooth which cannot be isolated.
- •Teeth with marginal periodontitis or crestal bone loss.
- •Indication of post/ post and core restoration marginal periodontitis with attachment loss \>5mm.
- •Teeth with immature root or calcified canal.
- •Teeth with internal and external resorption.
- •No pulp exposure after caries excavation.
- •Uncontrolled bleeding after access cavity preparation after several minutes N
Arms & Interventions
MTA GROUP
Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.
Intervention: Mineral trioxide aggregate
BIODENTINE GROUP
Vital Pulpotomy will be done using Biodentine as pulp capping agent.
Intervention: Biodentine
PRF + MTA GROUP
Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
Intervention: Mineral trioxide aggregate
PRF + MTA GROUP
Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
Intervention: Platelet rich fibrin
PRF+ BIODENTINE GROUP
Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
Intervention: Biodentine
PRF+ BIODENTINE GROUP
Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
Intervention: Platelet rich fibrin
Outcomes
Primary Outcomes
EPT
Time Frame: change from baseline to 1day, 3 months, 6 months, 9 months
Electric pulp testing
cold test
Time Frame: change from baseline to 1day, 3 months, 6 months, 9 months
cold test
Secondary Outcomes
- Tender on percussion(change from baseline to 1day, 3 months, 6 months, 9 months)
- swelling(change from baseline to 1day, 3 months, 6 months, 9 months)